Biotech start-ups with next-generation platform technologies—such as new therapeutic delivery methods and machine-learning-enabled drug discovery—have captured the lion’s share of recent venture-capital (VC) investment in the industry. Start-ups with these technologies attracted nearly $35 billion in VC funding from 2019 to 2021, compared with $17 billion for other therapeutics such as immunology.
To read the article, see “What are the biotech investment themes that will shape the industry?,” June 10, 2022.